TGA Approves EPAX’S Omega-3 Oils For Use In Australia’s Complementary Medicine Products

Oils Available in Australia Through Pathway International

LYSAKER, Norway (August, 28, 2006) – EPAX AS, a world leading supplier of omega-3 concentrates, announced today that after 18 months of working closely with its Australian distributor Pathway International, the company has been granted regulatory approval from Australia’s Therapeutic Goods Administration (TGA). This approval allows EPAX’s range of omega-3 oils to be used in complementary medicine products in Australia.

The approval comes at a time of increasing consumer awareness of the health benefits of the omega-3 fatty acids EPA and DHA. There is now a substantial body of scientific evidence supporting the use of the omega-3 fatty acids EPA and DHA for cardiovascular health, joint health, mood health and brain health.

“The demand for omega-3 fatty acids is continuing to grow on a global basis,” said Bjorn Refsum, CEO of EPAX AS, “We are pleased customers in Australia will now have access to products from EPAX, as the company is known as one of the world’s leading suppliers of omega-3 concentrates.”

About EPAX AS
EPAX AS is headquartered in Lysaker, Norway and has a GMP-approved production facility in Alesund, Norway, which is approved for API production by the Norwegian Medicines Agency. EPAX AS offers concentrated Omega-3 EPA/DHA oils in the business-to-business segment under the brand name EPAX, available in a wide range of top quality formulas with different EPA/DHA ratios focused on specific health conditions. EPAX is also available in TG or EE versions, including TG oils that are available in a deodorized TG/N version, which is virtually without taste and smell. For further information on EPAX AS, its products or clinical studies visit www.epax.com or contact Gunilla Traberg at [email protected].

# # #

Contact: Ove Wikstrom
+47 22 53 49 00
[email protected]